Company / Shareholders' Equity
Aquestive Therapeutics, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$33.7M
FY2025
5-year range
-$118.6M / -$33.7M
FY2021-FY2025
Trend
+44.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Aquestive Therapeutics, Inc. reports negative total equity of -$34M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$34M in FY2025.
Improved from -$106M to -$34M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Aquestive Therapeutics, Inc.'s shareholders' equity has grown for 3 consecutive years.
- In FY2025, shareholders' equity increased 44.0% year-over-year.
- Peak shareholders' equity was recorded in FY2019.
- Lowest shareholders' equity in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$33.7M | +44.0% |
| FY2024 | -$60.2M | +43.5% |
| FY2023 | -$106.5M | +10.2% |
| FY2022 | -$118.6M | -144.5% |
| FY2021 | -$48.5M | -692.2% |
| FY2020 | -$6.1M | -160.7% |
| FY2019 | $10.1M | +114.7% |
| FY2018 | -$68.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026